Hemolytic Uremic Syndrome – Quick Consult |
|
|
|
Last Updated / Reviewed: June 2022
|
|
Definition
Key History
Key Physical Exam
Risk Factors for Hemolytic Uremic Syndrome (HUS)
Differential Diagnosis
Diagnostic Testing
Clinical Risk and Safety Pearls
Treatment
Complications
Hemolytic uremic syndrome (HUS) is primarily a disease of infancy and early childhood.
The triad of microangiopathic hemolytic anemia, thrombocytopenia, and acute renal
failure defines HUS. HUS is the most common cause of acute renal failure in children.
HUS is an uncommon disorder, with multiorgan involvement caused by intravascular
platelet aggregation. The most common cause of HUS is from a toxin (Shiga) produced
by the Escherichia coli serotype 0157:H7 and follows a prodromal episode of diarrhea
that is frequently bloody. HUS occurs most commonly in the summer months and in
rural versus urban populations. Thrombotic thrombocytopenic purpura (TTP) and HUS
are terms which are used interchangeably to describe essentially the same disease
process. The share a classic pentad: microangiopathic hemolytic anemia, consumptive
thrombocytopenia, neurologic signs, renal disease and fever. All 5 are present only
40% at any time during an exacerbation of the illness.
Back To Top
- Prodromal infectious disease, usually diarrhea (90%), less often URI
- Grossly bloody stool
- Reduced or absent urine output
- Seizures
|
- Rash
- Abdominal pain
- Neurologic signs – confusion, severe headache, seizures
|
Back To Top
- Abdominal tenderness
- Acute abdomen
- CHF
- Fever
- GI bleeding
|
- Hypertension
- Petechiae
- Purpura
- Vomiting
|
Back To Top
- Eating rare hamburgers
- Recent visit to a petting zoo
- Rural location
|
Back To Top
- Appendicitis
- Disseminated intravascular coagulation
- Enteric infections – salmonella, campylobacter, yersinia, amebiasis and
clostridium
difficile
|
- Henoch-Schönlein purpura (HSP)
- Systemic vasculitis
- Thrombocytopenia from other causes
- Ulcerative colitis
|
Back To Top
Text / literature information and recommendations include:
-
CBC – Hemoglobin typically < 8 g/dL (microangiopathic hemolytic anemia with fragmented RBC’s must have schistocytes),
thrombocytopenia (< 60,000/mcL)
-
Peripheral smear – Schistocytes, helmet cells
-
Coombs test – Negative
-
UA – Hematuria, protein, leukocytes
-
BUN/Creatinine – Elevated
-
LDH – Typically very high
-
PT/PTT – Within normal range, differentiating HUS from DIC
-
Reticulocyte count – Elevated
Back To Top
- The diagnosis of HUS should be considered in a patient with a recent history of
diarrhea who presents with decreasing urine volume despite being adequately
hydrated.
- The diagnosis of HUS should be considered in a patient with a recent history of
diarrhea who presents with signs of a multisystem disorder, and/or neurological
symptoms.
- Antibiotics are not effective except for certain forms cause by Shigella
dysenteriae.
Antibiotics may increase the risk of developing HUS in children with E coli 0157:H7
colitis. Bactrim may increase verotoxin production by E coli 0157:H7.
- Mortality rate is between 5 and 15%.
- 85% of children with HUS recover after supportive therapy alone.
- Adults with HUS have a poorer prognosis than children. Treat like TTP with
plasmapheresis.
Back To Top
Common text / literature recommendations include:
- Supportive management with careful management of fluid status directed
toward an
euvolemic status
- Treatment of blood pressure elevation if present – calcium channel blockers
are
the initial choice. ACE inhibitors are not recommended because of the
concern of
reduced renal perfusion although this remains controversial. Some experts
feel ACE
inhibitors may have a renal protective effect.
- Dialysis for acute renal failure
- Plasmaphoresis may be needed for severe cases (children with significant
neurologic
symptoms), older children and adults. Plasma Infusion or Exchange:
- Infusion - Presumably adds a substance deficient in TTP patients
- Exchange - allows a large volume of plasma to be administered without
volume overload.
Also may remove toxic substances in plasma
- Exchange 1-1.5 times the predicted plasma volume with fresh frozen
plasma (FFP)
- Plasma exchange may be initiated even if there is uncertainty about the
diagnosis.
- Treatment with plasma exchange should be continued until the clinical
condition
and neurologic manifestations improve, and the platelet count rises.
- In a recent study, patients required an average of 8 treatments, with
the replacement
of 190 units of FFP.
- If plasma exchange is not immediately available, FFP (30ml/Kg) should be
administered.
- A diuretic may be necessary to prevent fluid overload, as large volumes of
FFP will
be needed.
- Blood transfusion if symptomatic – watch for fluid overload and
hyperkalemia.
- Blood transfusion is recommended for hemoglobin level less than 6 g/dL
to avoid
cardiac and pulmonary compromise. About 80% of patients with HUS require
transfusions.
Post transfusion goal of 8 to 9 g/dL is recommended. Blood transfusions
should be
given slowly and cautiously with frequent monitoring of the patient’s
vital signs.
- Platelet transfusion if actively bleeding and count less than 50,000 – rare
occurrence.
This should only be performed in consultation with specialist. May cause
life-threatening
hemorrhage.
- Consultation with hematologist and nephrologist
- NO antibiotics and NO anti-motility drugs
- Steroids may be of some benefit and should be initiated.
Back To Top
- Acute and chronic renal failure
- Bowel necrosis
- Bowel perforation
- Cardiac dysfunction
- Hemorrhagic colitis
|
- Intussusception
- Liver dysfunction
- Neurologic dysfunction
- Pancreatic dysfunction
|
Back To Top
|
|
|